DENALI THERAPEUTICS INC (DNLI) Stock News

USA - NASDAQ:DNLI - US24823R1059 - Common Stock

15.365 USD

-0.81 (-4.98%)

Last: 10/10/2025, 3:59:05 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DNLI Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Zacks Investment Research - Mentions: MNKD

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?

2 months ago - By: Zacks Investment Research - Mentions: BIIB CRMD

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26

2 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

2 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

2 months ago - By: Zacks Investment Research - Mentions: CPRX ACAD

Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?

2 months ago - By: Yahoo Finance

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy

3 months ago - By: Yahoo Finance

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target

3 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

9 months ago - By: Benzinga - Mentions: JPM

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

4 months ago - By: Zacks Investment Research - Mentions: MRNA

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?

5 months ago - By: Zacks Investment Research - Mentions: SNY BIIB

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus

5 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

5 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

6 months ago - By: Benzinga

What Happened To Denali Therapeutics Stock Wednesday?

6 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

6 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

7 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

7 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

8 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

8 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

8 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

9 months ago - By: Investor's Business Daily - Mentions: BIIB IONS

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

10 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

10 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

a year ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights